This is a preprint.
The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner
- PMID: 38826286
- PMCID: PMC11142068
- DOI: 10.1101/2024.05.17.594690
The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner
Update in
-
The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.Front Endocrinol (Lausanne). 2024 Jul 22;15:1432928. doi: 10.3389/fendo.2024.1432928. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39104812 Free PMC article.
Abstract
We recently reported that a novel chimeric peptide (GEP44) targeting both the glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y1- and Y2 receptor (Y1R and Y2R) reduced energy intake and body weight (BW) in diet-induced obese (DIO) rats. We hypothesized that GEP44 reduces energy intake and BW primarily through a GLP-1R dependent mechanism. To test this hypothesis, GLP-1R +/+ mice and GLP-1R null (GLP-1R -/- ) mice were fed a high fat diet for 4 months to elicit diet-induced obesity prior to undergoing a sequential 3-day vehicle period, 3-day drug treatment (5, 10, 20 or 50 nmol/kg; GEP44 vs the selective GLP-1R agonist, exendin-4) and a 3-day washout. Energy intake, BW, core temperature and activity were measured daily. GEP44 (10, 20 and 50 nmol/kg) reduced BW after 3-day treatment in DIO male GLP-1R +/+ mice by - 1.5±0.6, -1.3±0.4 and -1.9±0.4 grams, respectively ( P <0.05), with similar effects being observed in female GLP-1R +/+ mice. These effects were absent in male and female DIO GLP-1R -/- mice suggesting that GLP-1R signaling contributes to GEP44-elicited reduction of BW. Further, GEP44 decreased energy intake in both male and female DIO GLP-1R +/+ mice, but GEP44 appeared to produce more consistent effects across multiple doses in males. In GLP-1R -/- mice, the effects of GEP44 on energy intake were only observed in males and not females, suggesting that GEP44 may reduce energy intake, in part, through a GLP-1R independent mechanism in males. In addition, GEP44 reduced core temperature and activity in both male and female GLP-1R +/+ mice suggesting that it may also reduce energy expenditure. Lastly, we show that GEP44 reduced fasting blood glucose in DIO male and female mice through GLP-1R. Together, these findings support the hypothesis that the chimeric peptide, GEP44, reduces energy intake, BW, core temperature, and glucose levels in male and female DIO mice primarily through a GLP-1R dependent mechanism.
Similar articles
-
The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.Front Endocrinol (Lausanne). 2024 Jul 22;15:1432928. doi: 10.3389/fendo.2024.1432928. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39104812 Free PMC article.
-
The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats.Int J Mol Sci. 2025 Mar 26;26(7):3032. doi: 10.3390/ijms26073032. Int J Mol Sci. 2025. PMID: 40243702 Free PMC article.
-
The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats.bioRxiv [Preprint]. 2025 Feb 22:2025.01.06.631534. doi: 10.1101/2025.01.06.631534. bioRxiv. 2025. Update in: Int J Mol Sci. 2025 Mar 26;26(7):3032. doi: 10.3390/ijms26073032. PMID: 39829931 Free PMC article. Updated. Preprint.
-
Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.Clin Nutr. 2024 Jul;43(7):1782-1790. doi: 10.1016/j.clnu.2024.05.035. Epub 2024 May 28. Clin Nutr. 2024. PMID: 38861891 Free PMC article.
-
Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.Diabetes Obes Metab. 2018 Aug;20(8):1836-1851. doi: 10.1111/dom.13212. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938884 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials